Annovis Bio, INC Schedule 13G passive stakes

Highbridge Capital Management, LLC has reported beneficial ownership of 6.1% of Annovis Bio, Inc.'s common stock, primarily through exercised warrants.

Empery Asset Management, LP and Ryan M. Lane report a 5.64% stake in Annovis Bio, Inc. as of June 30, 2026.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 4.9% beneficial ownership stake in Annovis Bio, Inc., primarily through warrants, as detailed in an amended Schedule 13G filing.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a passive beneficial ownership of 5.1% in Annovis Bio, Inc., totaling 1,000,000 shares of common stock.